Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing

E-ISSN： 1532-6535|96|5|542-548

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.96, Iss.5, 2014-11, pp. : 542-548

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 5, 2013-05 ,pp. : 402-408

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 103, Iss. 2, 2018-02 ,pp. : 349-349

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 6, 2013-12 ,pp. : 640-645

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 4, 2013-04 ,pp. : 324-325

John Wiley & Sons Inc

Access to resources Recommend Favorite

High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing

By Ruañño Gualberto Thompson Paul D Villagra David Bower Bruce Kocherla Mohan Yazdanpanah Golriz Seip Richard L Windemuth Andreas White C Michael Duconge Jorge Holford Theodore R Wu Alan HB

Personalized Medicine, Vol. 5, Iss. 3, 2008-05 ,pp. : 225-232

Future Medicine

Access to resources Recommend Favorite